Výsledky léčby diabetického makulárního edému pomocí intravitreální aplikace ranibizumabu – roční zkušenosti
| Title in English | Results of Treatment of Diabetic Macular Edema Using Intravitreal Ranibizumab – One Year Results |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Diabetologie - Metabolismus - Endokrinologie - Výživa |
| MU Faculty or unit | |
| Citation | |
| Field | ORL, ophthalmology, stomatology |
| Keywords | diabetic macular oedema; ranibizumab; DME; diabetic retinopathy |
| Description | A new option in the treatment of diabetic macular oedema is the intravitreal application of ranibizumab (Lucentis). Patients and methods: This is a retrospective study of patients with diabetic macular edema (DME) treated with ranibizumab. We used Wilcoxon test for the statistical evaluation.The study group consist of 17 patients, average age 67 years, SD ± 7,11 women (65%) and 6 men (35%). The average follow-up period was 7 months, SD ±4 months. Results: The average initial best-corrected visual acuity (BCVA) was 28 ETDRS letters, SD ± 8, central retinal thickness (CRT) was 476 Mm, SD ± 95. On the day of the third injection of Lucentis BCVA was 34 ETDRS letters, SD ± 8, CRT 328 urn, SD ± 72 Three months after the third intravitreal injection BCVA was 31 ETDRS letters, SD ± 6, 380 urn CRT, SD ± 130. After 8 months from the beginning of treatment BCVA was 31 ETDRS letters, SD ± 9, CRT 386 urn, SD ± 148 One year after first injection the mean BCVA was 34 ETDRS letters, SD ± 6 CRT 321 um SD ± 64 average number of doses of ranibizumab during the observation period was 7 ± SD 4. We demonstrated a statistically significant difference between the initial visual acuity and BCVA on the day of the third injection (p = 0.004). We found statistically significant results between initial CRT and CRT on the day of the third injection (p < 0.001), after 5 months CRT (p = 0.008) and after 8 months from start of treatment (p =,018). Conclusion: Ranibizumab is an effective treatment for diabetic ocular oedema. |